Supernus Pharmaceuticals, Inc. (0LB2.L) LSE
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
Valuation
| Market Cap | 2.85B |
| Enterprise Value | 2.76B |
| P/E Ratio | -94.76 |
| PEG Ratio | 0.97 |
| Price/Sales Ratio | 3.62 |
| Price/Book Ratio | 2.59 |
| Enterprise/Revenue | 3.44 |
| Enterprise/EBITDA | 51.57 |
Fiscal Year
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | March 31, 2026 |
Profitability
| Profit Margin | -0.04 |
| Operating Margin | -0.05 |
AD
Management Effectiveness
| Return On Assets | -0.02 |
| Return On Equity | -0.03 |
Income Statement
| Revenue | 718.95M |
| Revenue/Share | 13.48 |
| Gross Profit | 644.39M |
| EBITDA | 54.4M |
| Net Income | -38.55M |
| Diluted EPS | -0.68 |
Balance Sheet
| Total Cash | 384.24M |
| Total Cash/Share | 6.67 |
| Total Debt | 40.9M |
| Total Debt/Equity | 0.04 |
| Current Ratio | 1.96 |
| Book Value Per Share | 18.68 |
Price History
| 52-Week Change | 45.97 |
| 52-Week High | 47.95 |
| 52-Week Low | 22.54 |
| Moving Average 50 Days | 27.93 |
| Moving Average 200 Days | 29.84 |
Statistics
| Average Volume | 83 |
| Shares Outstanding | 56.9M |
| % Held by Institutions | N/A |
Dividend And Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |
AD
